Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma

The discovery of activating BRAF V600E mutations in 50% of all melanoma patients and the development of small molecule BRAF inhibitors looks set to revolutionize the therapy of disseminated melanoma. However, in the recent clinical trial of the BRAF inhibitor, vemurafenib (PLX4032), a significant pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Koomen, John M., Smalley, Keiran S. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2011
Materias:
Research Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248164/
https://www.ncbi.nlm.nih.gov/pubmed/21505227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248164/
https://www.ncbi.nlm.nih.gov/pubmed/21505227

Ejemplares similares